China’s biotechnology market has “significantly” driven up the demand for primate experimental models as the market recovers, tightening the supply of laboratory monkeys, according to a leading biotech firm.
Primate experiments typically use monkeys and other non-human species to test the safety and efficacy of a drug under development before clinical trials on humans.
Over US$110 billion worth of Chinese-developed drug candidates were traded in 81 out-licensing deals in the first half of the year, equivalent to 80 per cent of the full-year value in 2025, data from China’s National Medical Products Administration showed.
Joinn added that the price increase resulted from the tightened supply of non-human primates for experimental use in China, as their breeding rate has remained relatively stable.


Don't Miss:
-
Survivors Recount 22 Days of Kidnapping and Torture in Guerrero
-
Organized Crime Postponed Democracy in Haiti, Again
-
Organized Crime Postponed Democracy in Haiti, Again | The InSight Take
-
Unstoppable Violence in Michoacán: 31 Police Officers Killed, and Criticism of the Government Mounts
-
A Total of 13 Mass Graves Have Been Found in Viesca Containing the Charred Remains of Men and Women

Anwar Ibrahim: The Man Who Became the Compromise
The US is letting a convicted Bolsonaro spy chief stay in Florida. Brazil wants answers.
Rick Claypool on Pay to Play Corporate Crime Enforcement